3-05 Industrial Parkway South
Aurora, Ontario, Canada, L4G 6X7
August 6, 2010
HELIX BIOPHARMA CLOSES $11.0 MILLION PRIVATE
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: “HXBPF”) today announced that it
has closed a private placement of 4,530,000 units at $2.43 per unit.
Each unit consists of one common share and one common share purchase warrant, with each common share
purchase warrant entitling the holder to purchase, subject to adjustment, one common share of the Company at a
price of $3.402 for up to three years after the closing date of the private placement. Net proceeds after
expenses are expected to be approximately $9.5 million and will be used for working capital, primarily to support
the Company’s expanding clinical trial initiatives.
As a result of the placement, Mr. Zbigniew Lobacz has become an “insider” of Helix as he now holds more than
10% of Helix’s outstanding common shares. A separate news release is being issued by him in connection with
The securities offered will not be and have not been registered under the United States Securities Act of 1933, as
amended, or the securities laws of any state of the United States, and may not be offered or sold in the United
States or to a U.S. person absent registration or an applicable exemption from registration requirements. The
distribution of the securities offered is exempted from provincial securities laws in Canada.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company focused on cancer therapy. The Company is actively
developing innovative products for the prevention and treatment of cancer based on its proprietary
technologies. Helix’s product development initiatives include its Topical Interferon Alpha- 2b and its novel L-
DOS47 new drug candidate. Helix is listed on th